Core Viewpoint - Blackbird Critical Metals Corp. has received conditional approval from the Canadian Securities Exchange for its acquisition of Lir Life Science Inc. and the listing of the resulting issuer's common shares upon completion of the acquisition [1][11]. Acquisition Details - The company will acquire 100% of Lir Life Sciences' common shares in exchange for issuing 22,312,678 common shares of Blackbird on a post-consolidation basis to Lir shareholders [3]. - Following the acquisition, the business will continue under the name "Lir Life Sciences Corp." [3]. Share Consolidation - Prior to the acquisition closing, Blackbird will consolidate its shares on a 1.5:1 basis, reducing the number of outstanding shares from approximately 7,762,912 to about 5,175,275 [4][5]. - Registered shareholders will receive instructions for exchanging their existing certificates for post-consolidation shares [6]. Financial Transactions - The acquisition includes a transaction fee of 2% of the acquisition value, payable in 379,000 Resulting Issuer Shares [8]. - Lir Life Sciences has completed a private placement of 3,050,270 subscription receipts at $0.35 each, raising approximately $1.07 million, which will convert into Lir Shares prior to closing [9]. - Lir Life Sciences has settled $109,343 in debt by issuing 312,408 Lir Shares at a deemed price of $0.35, which will also convert into Resulting Issuer Shares upon closing [10]. Trading and Regulatory Approval - Trading in Blackbird Shares will remain halted until all conditions for listing are satisfied, including the completion of the acquisition and final approval from the CSE [11]. - The new CUSIP and ISIN numbers for the post-consolidation shares will be 50206C100 and CA50206C1005, respectively [7].

Core Insights - Argenta Silver Corp. has successfully completed its first year of operations, establishing a strong team and gaining recognition in the market [6][20] - The company aims to become a leading silver producer in Latin America, focusing on exploration and production across multiple operations [8] - Significant financial backing has been secured, with C$35 million raised, of which only C$12 million has been spent on operations and acquisitions [10] Company History and Development - The acquisition of the El Quevar Project was finalized on October 24, 2024, marking a pivotal moment for Argenta Silver [2][20] - The company has built a culturally diverse team and established a reputation for transparency and results, attracting major institutional investors [6][9] - The CEO, Joaquin Marias, has a background in geology and has been involved in the El Quevar project since 2010 [3][4] Financial Performance and Capital Allocation - Argenta Silver raised C$15.3 million through a private placement to capitalize the company, with significant investments from notable shareholders [2][10] - The company plans to allocate approximately 40% of its upcoming capital expenditure towards resource expansion and 60% towards exploration [14] Exploration and Technical Achievements - The company has conducted extensive geological work, including re-logging 29,000 meters of historical drill core and detailed mapping of 133 km² [10] - Recent drilling results have shown high silver grades, with surface results exceeding 20,000 g/t Ag and notable drill intercepts of 1.05 meters at 18,467 g/t Ag [18] - The foundational mineral resource estimate of the Yaxtché deposit includes an indicated resource of 45.3 million ounces of silver at a grade of 482 g/t Ag [21] Future Plans and Vision - Argenta Silver is set to embark on a larger drilling campaign, planning 12,000 to 15,000 meters of drilling and geophysical surveys in previously unexplored areas [13][14] - The company aims to unlock the potential of the El Quevar project, which has been dormant for ten years under previous management [16] - The strategic approach focuses on balancing resource area drilling with exploration to maximize value and uncover new deposits [17]

Core Viewpoint - Helix BioPharma Corp. reported a net loss of $5,205,000 for the fiscal year ended July 31, 2025, showing an improvement from a loss of $9,264,000 in the previous year, indicating progress in financial management and operational focus [2][13]. Financial Performance - The total comprehensive loss for the year was $5,205,000, translating to a loss of $0.09 per common share, compared to a loss of $0.21 per common share in the previous year [2][13]. - Research and Development expenses decreased by 40% to $3,558,000 from $5,977,000 in the previous year, attributed to the conclusion of a Phase Ib/II study and changes in stock-based compensation [8][9]. - Operating, general, and administration expenses also saw a significant reduction of 43%, totaling $1,839,000 compared to $3,262,000 in the prior year, primarily due to changes in service providers [10][11]. Clinical Development - The Phase Ib/II trial (LDOS006) for metastatic pancreatic adenocarcinoma was completed in October 2024, with ongoing data analysis and a Clinical Study Report expected in fall 2025 [3]. - A new Phase Ib/Randomized Phase II study (LDOS007) is in planning to assess L-DOS47 in combination with pembrolizumab for NSCLC, with positive feedback received from the FDA regarding the study design [4][6]. Corporate Development - The company decided to focus on developing L-DOS47 as a combination therapy for NSCLC, terminating collaborations with external research institutions that did not align with this focus [6]. - The company closed its laboratory in Edmonton, Canada, on October 31, 2024, and liquidated laboratory equipment while securing important documents and samples [6]. Capital and Liquidity - As of July 31, 2025, the company reported a working capital deficiency of $2,807,000 and an accumulated deficit of $215,876,000, indicating challenges in liquidity [13][18]. - The company closed a non-brokered private placement of 2,222,333 common shares at $0.75 per share, raising gross proceeds of $1,667,000 [7]. Research & Development Focus - The company’s pipeline includes L-DOS47, which targets CEACAM6-expressing tumors, and two pre-IND candidates: LEUMUNA™ and GEMCEDA™, aimed at addressing significant unmet medical needs in oncology [20].

Core Points - Baru Gold Corp. has appointed Keith Margetson to its board of directors, bringing over 40 years of public accounting experience [1][2] - Margetson has served as CFO for several publicly traded companies and is a qualified Canadian CPA and US Certified Public Accountant [2] - The company granted 300,000 stock options to Margetson, allowing him to purchase shares at an exercise price of $0.07 for two years, pending TSX Venture Exchange approval [2] Company Overview - Baru Gold Corporation is a junior gold developer with NI 43-101 gold resources located in Indonesia, a leading gold-producing country [3] - The company is based in both Indonesia and North America, with a team experienced in operating small-scale gold and coal assets [3] - Baru is positioned to become Indonesia's next gold producer, indicating growth potential in the mining sector [3]

Core Points - Hi-View Resources Inc. will present and host an exhibitor booth at the 51st Annual New Orleans Investment Conference from November 2–5, 2025 [1] - The corporate presentation titled "Unlocking District-Scale Gold, Silver, and Copper Opportunities in BC's Prolific Toodoggone District" is scheduled for November 5th at 9:40 a.m. [2] - CEO R. Nick Horsley expressed excitement about participating in the conference and highlighted Hi-View as a below-the-radar investment opportunity compared to peers [3] Company Overview - Hi-View Resources Inc. is a publicly listed mineral exploration company on the Canadian Securities Exchange, focusing on gold, silver, and copper assets in the Toodoggone region of northern British Columbia [6] - The company holds 100% ownership or options on projects covering over 27,791 hectares, including the flagship Golden Stranger Project, Lawyers claims, and Borealis Project, all designated as high-priority targets [6] - Additional properties under option include Saunders, Northern Claims, Nub, and Harmon Peak, with an extra 1,300 hectares currently under mineral claim application [6]

Core Insights - Ventripoint Diagnostics Ltd. has partnered with Providence Health Care Ventures to validate its VMS+™ platform at St. Paul's Hospital, aiming to reduce reliance on cardiac MRI through AI-enhanced echocardiography [1][4] - The VMS+™ platform generates 3-D heart models from 2-D echocardiography images and has shown clinical agreement with MRI measurements, potentially allowing some patients to avoid MRI altogether [2][3] - The collaboration seeks to assess the performance of VMS+™ in real-world settings, focusing on workflow integration, MRI referral reductions, and cost efficiencies [4][5] Company Overview - Ventripoint is recognized for its application of AI in echocardiography, with its VMS products utilizing proprietary Knowledge Based Reconstruction technology to provide accurate cardiac measurements comparable to MRI [7][8] - The VMS+™ platform is FDA-cleared and Health Canada-licensed, compatible with existing 2D ultrasound systems, which allows healthcare systems to enhance imaging capacity without the need for new equipment [2][8] Clinical Evidence - VMS+™ has been successfully implemented in various clinical settings, including the Hospital for Sick Children and Mayo Clinic, demonstrating its effectiveness in aligning echo-derived measurements with cardiac MRI [3] - Recent presentations at conferences have highlighted the platform's ability to provide results comparable to MRI, particularly in assessing adult congenital heart defect patients [3] Future Prospects - The collaboration with PHC Ventures is set to begin in November 2025, with implementation expected in early 2026, aiming to validate the impact of VMS+™ across different healthcare settings [6] - The technology is anticipated to improve access to advanced cardiac diagnostics, especially in rural and Indigenous communities where MRI availability is limited [5][6]

Core Viewpoint - Tribeca Resources Corporation has entered into a definitive option agreement to acquire a 100% interest in the Jiguata Porphyry Copper property in northern Chile, with plans for significant exploration activities over the next year [1][2]. Option Agreement Details - The option agreement spans 5 years, allowing Tribeca to acquire the Jiguata Property, which covers 10,000 hectares [1][5]. - An initial payment of US$25,000 has been made, with an additional reimbursement of approximately US$44,000 for the 2025 license fee [2][4]. - Total cash payments and work commitments are structured over the five years, with specific milestones including: - Year 1: US$75,000 - Year 2: US$125,000 and a minimum of 3,000 meters of drilling - Year 3: US$175,000 - Year 5: US$14,450,000 if the purchase option is exercised [3][4]. Exploration Potential - The Jiguata Property is located in a region known for significant copper deposits, near major mines such as Collahuasi and Quebrada Blanca [2][5]. - The property features a large exploration target zone of 5km x 3km, with two near drill-ready targets identified through soil sampling and geological mapping [3][6]. - Pre-drilling activities will include historic mapping, surface sampling, and additional geophysics [7]. Strategic Positioning - The acquisition of the Jiguata Property expands Tribeca's portfolio to three high-potential copper projects in Chile, enhancing its ability to capitalize on the growing interest in copper exploration [2][3]. - The company plans to conduct drilling at both the Jiguata and its flagship La Higuera Property in the coming months, indicating a period of high activity [2][3].

Core Insights - Cascade Copper Corp. has announced positive results from its summer 2025 field program at the Copper Plateau Porphyry project, indicating potential resource expansion areas [2][3][4] Project Overview - The Copper Plateau Porphyry project spans 2,789 hectares and is located in south-central British Columbia, Canada [2][5] - The project is situated near the former Brenda Copper Mine, which produced 177 million tonnes of ore with a grade of 0.169% Cu and 0.043% Mo from 1970 to 1990 [5] Sample Results - Seven samples were collected, with five returning highly anomalous assays, including: - Sample A0284805: 10.6% Cu, 0.58 g/t Au, 66.9 g/t Ag, 0.18% Mo, equating to 13.04% CuEq - Sample A0284803: 0.86% Cu, 0.28 g/t Au, 7.12 g/t Ag, 23.9 ppm Mo, equating to 1.22% CuEq [4][12] - The results confirm that historic soil sampling aligns with significant bedrock mineralization [4][18] Future Plans - The company plans to conduct an induced polarization (IP) survey and several drill holes to explore high-grade potential areas indicated by historic drilling [14] - Permitting for geophysical surveys and drilling is currently underway [14] Exploration Strategy - Cascade Copper focuses on modern exploration techniques, including 3D inversion modeling and AI-enhanced predictive modeling [19] - The company is engaged in evaluating and exploring copper and gold mineral resource properties in British Columbia and Ontario [19]

Core Insights - SuperQ Quantum Computing Inc. has engaged Winning Media LLC for digital marketing services to enhance market and brand awareness [1][2] - The agreement with Winning Media is effective from October 28, 2025, until December 1, 2025, with a fee of US$50,000 paid for the services [2] - SuperQ aims to position itself as a leader in quantum and supercomputing solutions for global organizations [4][5] Company Overview - SuperQ Quantum Computing Inc. is focused on enterprise transformation through quantum and supercomputing technologies [4] - The flagship Super™ platform is designed to provide advanced computational power that is intuitive and accessible for various sectors including finance, healthcare, and defense [5] - The company is headquartered in Canada and is expanding its presence internationally, particularly in the US, Middle East, and Asia [5]

Core Viewpoint - Anonymous Intelligence Company Inc. has received approval to extend the closing date of its non-brokered private placement under the Listed Issuer Financing Exemption to November 10, 2025, to accommodate additional investor interest [1][2]. Group 1: Offering Details - The LIFE Offering will consist of 1,750,000 units priced at $0.20 per unit, aiming for gross proceeds of $350,000, with a potential increase of up to 50% or an additional 875,000 units, bringing total gross proceeds to $525,000 [3]. - Each unit will include one common share and one common share purchase warrant, with the warrant allowing the holder to acquire an additional common share at an exercise price of $0.25 for 24 months [4]. - The offering is being conducted under the Listed Issuer Financing Exemption, and the securities issued will not have resale restrictions under Canadian securities laws [5]. Group 2: Use of Proceeds - Net proceeds from the LIFE Offering are expected to be allocated towards product development, marketing, rebranding, investor communications, cryptocurrency initiatives through the SimpliiCrypto platform, and general administrative expenses [6]. Group 3: Insider Participation - Certain insiders of the company plan to participate in the LIFE Offering, which will be classified as a "related party transaction" under Multilateral Instrument 61-101, with the company relying on exemptions from formal valuation and minority shareholder approval requirements [7]. Group 4: Company Overview - Anonymous Intelligence Company Inc. focuses on developing decentralized network infrastructure, data storage solutions, and privacy-enhancing AI tools, aiming to empower users with confidence in technology while prioritizing privacy and data security [9][10].